Overexpression of stathmin 1 is a poor prognostic biomarker in non-small cell lung cancer

Laboratory Investigation

Volumn 95, Issue 1, 2015, Pages 56-64

  Nie, Wei ^a   Xu, Mi Die ^b,c,d   Gan, Lu ^b,c   Huang, Hai ^e   Xiu, Qingyu ^e   Li, Bing ^e  

^a No 425 Hospital of Chinese PLA   (China)

^b FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^c FUDAN UNIVERSITY   (China)

^d FUDAN UNIVERSITY   (China)

^e SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

SMALL INTERFERING RNA; STATHMIN; STATHMIN 1; UNCLASSIFIED DRUG; MESSENGER RNA; PRIMER DNA; STMN1 PROTEIN, HUMAN; TUMOR MARKER;

ARTICLE; CANCER SIZE; CELL CULTURE; CELL PROLIFERATION; CELL PROLIFERATION ASSAY; CONTROLLED STUDY; DISEASE SPECIFIC SURVIVAL; FOLLOW UP; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MICROTUBULE; NON SMALL CELL LUNG CANCER; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR DIFFERENTIATION; WESTERN BLOTTING; FEMALE; GENETICS; LUNG TUMOR; MALE; METABOLISM; MIDDLE AGED; NUCLEOTIDE SEQUENCE; PATHOLOGY; PROGNOSIS; TUMOR CELL LINE;

BASE SEQUENCE; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; DNA PRIMERS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; STATHMIN; TUMOR MARKERS, BIOLOGICAL;

EID: 84920075438     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2014.124     Document Type: Article

References (20)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30.
2. Belmont LD, Mitchison TJ. Identification of a protein that interacts with tubulin dimers and increases the catastrophe rate of microtubules. Cell 1996;84:623-631.
3. Jeon TY, Han ME, Lee YW, et al. Overexpression of stathmin1 in the diffuse type of gastric cancer and its roles in proliferation and migration of gastric cancer cells. Br J Cancer 2010;102:710-718.
4. Hsu HP, Li CF, Lee SW, et al. Overexpression of stathmin 1 confers an independent prognostic indicator in nasopharyngeal carcinoma. Tumour Biol 2014;35:2619-2629.
5. Zheng P, Liu YX, Chen L, et al. Stathmin, a new target of PRL-3 identified by proteomic methods, plays a key role in progression and metastasis of colorectal cancer. J Proteome Res 2010;9:4897-4905.
6. Salvesen HB, Carter SL, Mannelqvist M, et al. Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation. Proc Natl Acad Sci USA 2009;106:4834-4839.
7. Kang W, Tong JH, Chan AW, et al. Stathmin1 plays oncogenic role and is a target of microRNA-223 in gastric cancer. PLoS One 2012;7: e33919.
8. Ke B, Wu LL, Liu N, et al. Overexpression of stathmin 1 is associated with poor prognosis of patients with gastric cancer. Tumour Biol 2013;34:3137-3145.
9. Chen G, Wang H, Gharib TG, et al. Overexpression of oncoprotein 18 correlates with poor differentiation in lung adenocarcinomas. Mol Cell Proteomics 2003;2:107-116.
10. Brambilla E, Travis WD, Colby TV, et al. The new World Health Organization classification of lung tumours. Eur Respir J 2001;18: 1059-1068.
11. Goldstraw P, Crowley J, Chansky K, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2007;2:706-714.
12. Allred DC, Clark GM, Elledge R, et al. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 1993;85:200-206.
13. Hsieh SY, Huang SF, Yu MC, et al. Stathmin1 overexpression associated with polyploidy, tumor-cell invasion, early recurrence, and poor prognosis in human hepatoma. Mol Carcinog 2010;49:476-487.
14. Yuan RH, Jeng YM, Chen HL, et al. Stathmin overexpression cooperates with p53 mutation and osteopontin overexpression, and is associated with tumour progression, early recurrence, and poor prognosis in hepatocellular carcinoma. J Pathol 2006;209:549-558.
15. Martello LA, Verdier-Pinard P, Shen HJ, et al. Elevated levels of microtubule destabilizing factors in a Taxol-resistant/dependent A549 cell line with an alpha-tubulin mutation. Cancer Res 2003;63: 1207-1213.
16. Pu X, Wang J, Xu L, et al. Relationship between expression of betatubulin-III plus stathmin in advanced non-small cell lung cancer and its sensitivity to venorelbine chemotherapy. Zhongguo Fei Ai Za Zhi 2009;12:49-53.
17. Rosell R, Scagliotti G, Danenberg KD, et al. Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-smallcell lung cancer. Oncogene 2003;22:3548-3553.
18. Jiang H, Yu XM, Zhou XM, et al. Correlation between microtubuleassociated gene expression and chemosensitivity of patients with stage II non-small cell lung cancer. Exp Ther Med 2013;5:1506-1510.
19. Kouzu Y, Uzawa K, Koike H, et al. Overexpression of stathmin in oral squamous-cell carcinoma: correlation with tumour progression and poor prognosis. Br J Cancer 2006;94:717-723.
20. Belletti B, Baldassarre G. Stathmin: a protein with many tasks. New biomarker and potential target in cancer. Expert Opin Ther Targets 2011;15:1249-1266.